🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase II trial tests the effectiveness of odronextamab given before ch...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
Start Date
2025-09-04
Trial ID
NCT06784726
This phase II trial tests the safety and effectiveness of giving chemothera...
Status
Withdrawn
Location
Multiple Locations
Start Date
2024-08-09
Trial ID
NCT06210750
Treatments Being Tested
This phase I trial tests the safety, side effects, and best dose of allogen...
Status
Suspended
Location
City of Hope Medical Center
Start Date
2024-02-19
Trial ID
NCT05993611
This phase II trial tests how well darolutamide in combination with leuprol...
Status
Active Not Recruiting
Location
Cedars-Sinai Medical Center
Start Date
2024-02-08
Trial ID
NCT06169124
This phase Ib/II trial studies the side effects and best dose of venetoclax...
Status
Active Not Recruiting
Location
Anchorage Associates in Radiation Medicine
Start Date
2018-08-13
Trial ID
NCT03504644
The development of trastuzumab deruxtecan (T-DXd), an anti-HER2 conjugated ...
Status
Not Yet Recruiting
Location
ICANS
Start Date
2025-09
Trial ID
NCT07130344
Treatments Being Tested
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax...
Status
Recruiting
Location
Mayo Clinic in Rochester
Start Date
2024-01-04
Trial ID
NCT05910801
This phase II trial tests how well venetoclax works in treating patients wi...
Status
Recruiting
Location
City of Hope Comprehensive Cancer Center
Start Date
2024-12-16
Trial ID
NCT06311227
This phase I trial tests the safety, side effects and best dose of FH-WT1-E...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
Start Date
2026-09-01
Trial ID
NCT07645469
Treatments Being Tested
Background: Burkitt Lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL...
Status
Terminated
Location
National Institutes of Health Clinical Center
Start Date
2022-03-24
Trial ID
NCT04933617